Take the Kiralis Challenge

Are you involved in R&D or process development within these areas?


Kiralis is looking to partner with drug and active ingredient developers that are:

1 - in development of new complex enantiomers that are difficult to design

2 - developing complex processes for manufacturing enantiomers with multi-steps that include chromatographic separation

Kiralis is developing breakthrough applications for separation and facilitating synthesis through the use of Chiral Induced Spin Selectivity (CISS).

This provides a potential for better separation with higher purity, possible new ways of synthesizing larger enantiomers.

 
Arie Laor